combination

Armada Acquisition Corp. II Announces Ticker Symbol to Change to XRPN on Oct 30, 2025

New ticker aligns with new $1 billion strategy for XRP exposure on NASDAQ MIAMI, Oct. 29, 2025 /PRNewswire/ -- Armada Acquisition…

1 week ago

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust…

2 weeks ago

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies…

4 weeks ago

Celanese Designing the Future at K 2025

New materials and services empower customers to accelerate design innovations, meet complex performance requirements, and advance sustainability goalsDALLAS--(BUSINESS WIRE)--$CE--Celanese Corporation…

1 month ago

XED Welcomes Back Technology Visionary Mrinal Srivastava as Chief Technology Officer

NEW YORK and MUMBAI, India, Sept. 26, 2025 /PRNewswire/ -- XED is proud to announce the return of Mrinal Srivastava as…

1 month ago

IndoSpace expands presence with new 66-Acre Park in Maharashtra’s industrial and warehousing hub, Bhiwandi

MUMBAI, India, Sept. 26, 2025 /PRNewswire/ -- IndoSpace, India's fully integrated supply chain infrastructure services platform, has launched its new logistics…

1 month ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

September 20, 2025 11:00 ET  | Source: C4 Therapeutics, Inc. Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response…

2 months ago

Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid…

2 months ago

Olympism365: Six innovators awarded grants to advance UN SDGs through combination of sport and technology

16 September 2025 – Six recipients have received Tech365 Incubate grants, each worth up to USD 40,000, the International Olympic…

2 months ago